Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872511 | 0.85 | DPP4 (0.66) | DPP4HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL4770914 | 0.76 | DPP9 (0.54) | DPP4DPP7DPP9 | |
| Hydrochloric Acid SCHEMBL6164070 | 0.67 | HDAC8 (0.46) | DPP4HDAC8NLNRAD52 | |
| SCHEMBL4393088 | 0.67 | ALPI (0.54) | DPP4 | |
| SCHEMBL29574121 | 0.67 | ALPI (0.54) | DPP4 | |
| SCHEMBL29440959 | 0.67 | ALPI (0.54) | DPP4 | |
| SCHEMBL45382 | 0.67 | ALPI (0.54) | DPP4 | |
| SCHEMBL2700469 | 0.67 | ALPI (0.54) | DPP4 | |
| SCHEMBL12936626 | 0.66 | MTNR1A (0.54) | DPP4 | |
| SCHEMBL5295982 | 0.66 | TSHR (0.53) | DPP4RAD52UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |